Business
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
Ebvallo is the First and Only Approved Therapy in Europe for Adults and Children with EBV+ PTLD THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara
About this update from Atara Biotherapeutics, Inc.
[{"type":"text","content":"\nEbvallo is the First and Only Approved Therapy in Europe for Adults and Children with EBV+ PTLD\n\n\n THOUSAND OAKS, Calif.--(BUSINESS WIRE)--\nAtara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that EbvalloTM (tabelecleucel or tab-cel®) has been awarded the prestigious 2024 Prix Galien International Award for “Best Product for Orphan/Rare Diseases.” The award was presented to Pierre Fabre Laboratories, Atara’s global development and commercialization partner for Ebvallo.\n\n\nThe Prix Galien International Awards for Life Science Research is organized every two years and is judged by a committee of distinguished independent experts and specialists. They select the most innovative therapy from the winners of the 15 National Prix Galien awards in each category over the previous two years. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.\n\n\n“The Prix Galien International Award for Ebvallo highlights the importance of this first ever allogeneic T-cell therapy in potentially changing outcomes for patients that previously had no approved therapies in this treatment setting and poor overall survival,” said Pascal Touchon, President and Chief Executive Officer of Atara. “Receiving this award is a great honor and I want to thank Atara and Pierre Fabre teams that have worked to bring this important medicine to patients. Following Ebvallo approval and launch in Europe, we look forward to continuing our work together to expand patient access in the U.S. and other markets.”\n\n\nTab-cel was developed by Atara and was granted marketing authorization under the brand name Ebvallo™ in December 2022 by the European Commission indicated as a monotherapy for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein‑Barr virus positive post‑transplant lymphoproliferative disease (r/r EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.\n\n\nIn the U.S., Atara submitted a Biologics License Application in May 2024 to the U.S. Foo...